Medicenna Therapeutics Corp
MDNA
Company Profile
Business description
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL-13 Superkines and Empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. Its pipeline candidates include MDNA11 for Cancer immunotherapies, MDNA55 is a Molecular Trojan Horse, and BiSKITs represent a novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Contact
2 Bloor Street West
Suite 903
TorontoONM4W 3E2
CANT: +1 416 964-5442
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
17
Stocks News & Analysis
stocks
Meta earnings: Strong end to 2025 as AI monetization begins to show
Investors please with latest results.
stocks
Why doesn’t the market like the earnings from this US tech giant?
Good quarter with AI demand ramping.
stocks
Our Tesla fair value increases meaningfully
Progress on Robotaxi and Optimus shows real world AI growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,169.90 | 89.30 | -0.96% |
| CAC 40 | 8,071.36 | 4.68 | 0.06% |
| DAX 40 | 24,309.46 | 513.33 | -2.07% |
| Dow JONES (US) | 49,071.56 | 55.96 | 0.11% |
| FTSE 100 | 10,171.76 | 17.33 | 0.17% |
| HKSE | 27,556.28 | 411.81 | -1.47% |
| NASDAQ | 23,685.12 | 172.33 | -0.72% |
| Nikkei 225 | 52,923.12 | 452.48 | -0.85% |
| NZX 50 Index | 13,413.98 | 65.37 | 0.49% |
| S&P 500 | 6,969.01 | 9.02 | -0.13% |
| S&P/ASX 200 | 8,875.70 | 79.40 | -0.89% |
| SSE Composite Index | 4,104.10 | 53.88 | -1.30% |